MediFind

Find a Doctor

Swaminathan P. Iyer

Physicians Referral Service
Hematology, Internal Medicine
Male
Practicing approx. 24 years

Bio


Swaminathan Iyer is a Hematologist and an Internal Medicine specialist in Houston, Texas. He has been an author on 68 peer reviewed articles and participated in 1 clinical trials in the past 15 years. Dr. Iyer's top three areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Acute Myeloblastic Leukemia with Maturation. He is licensed to treat patients in TX and NY.

Contact

1515 Holcombe Blvd
Houston, TX 77030, US

Latest Research


Latest Advance
Study
  • Condition: Large B-Cell Lymphoma
  • Journal: Blood advances
  • Treatment Used: Axicabtagene Ciloleucel (axi-cel)
  • Number of Patients: 100
  • Published —
This study analyzed patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel).
Latest Advance
Study
  • Condition: Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
  • Journal: Blood
  • Treatment Used: Venetoclax-Obinutuzumab
  • Number of Patients: 82
  • Published —
This study evaluated the safety and tolerability of venetoclax-obinutuzumab in patients with relapsed/refractory (disease that returns/disease that doesn't respond to treatment; R/R) chronic lymphocytic leukemia (a type of cancer of the blood and bone marrow; CLL).
Latest Advance
Study
  • Condition: Relapsed Or Refractory B-cell Malignancies
  • Journal: Blood
  • Treatment Used: Parsaclisib
  • Number of Patients: 72
  • Published —
In this study, researchers evaluated the safety and effectiveness of parsaclisib for the treatment of relapsed or refractory B-cell malignancies.
Latest Advance
Study
  • Condition: CD30-positive peripheral T-cell lymphoma
  • Journal: Lancet (London, England)
  • Treatment Used: Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone
  • Number of Patients: 452
  • Published —
Researchers looked to deteremine the results from using the chemotherapy regimen of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus using cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of CD30-positive peripheral T-cell lymphoma.

Contact

1515 Holcombe Blvd
Houston, TX 77030, US

Affiliations

  • The University Of Texas M.d. Anderson Cancer Center

Credentials

  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Hematology
    Hematology/oncology

Insurance

Contact them to find out if they accept your insurance plan.